• LAST PRICE
    14.2800
  • TODAY'S CHANGE (%)
    Trending Down-0.4500 (-3.0550%)
  • Bid / Lots
    14.0900/ 1
  • Ask / Lots
    15.2100/ 1
  • Open / Previous Close
    14.8100 / 14.7300
  • Day Range
    Low 14.1300
    High 15.0695
  • 52 Week Range
    Low 12.9500
    High 25.4700
  • Volume
    489,198
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 14.73
TimeVolumeRCUS
02:24 ET10014.28
02:26 ET10014.26
02:27 ET20014.27
02:29 ET155714.23
02:31 ET70014.23
02:33 ET40014.23
02:36 ET60014.24
02:38 ET20014.24
02:40 ET90014.225
02:42 ET149414.18
02:44 ET185814.16
02:45 ET293014.175
02:47 ET30014.165
02:49 ET60614.19
02:51 ET155814.205
02:54 ET30014.2
02:56 ET100214.21
02:58 ET70014.2
03:02 ET50814.21
03:03 ET10014.195
03:05 ET91314.22
03:07 ET83314.19
03:09 ET156114.24
03:12 ET30014.245
03:14 ET60014.245
03:16 ET235014.26
03:18 ET237814.345
03:20 ET120014.34
03:21 ET61914.33
03:23 ET61314.32
03:25 ET80014.32
03:27 ET95614.325
03:30 ET223414.33
03:32 ET841914.335
03:34 ET213014.32
03:36 ET530014.3199
03:38 ET413914.305
03:41 ET152614.27
03:43 ET536314.27
03:45 ET70514.27
03:48 ET627114.22
03:50 ET351814.255
03:52 ET629414.33
03:54 ET572114.29
03:56 ET372014.26
03:57 ET566014.295
03:59 ET13373714.28
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRCUS
Arcus Biosciences Inc
1.4B
-4.6x
---
United StatesARDX
Ardelyx Inc
1.3B
-19.1x
---
United StatesGYRE
Gyre Therapeutics Inc
1.3B
-8.1x
---
United StatesVIR
Vir Biotechnology Inc
1.4B
-2.5x
---
United StatesNRIX
Nurix Therapeutics Inc
1.4B
-7.1x
---
United StatesPRTA
Prothena Corporation PLC
1.3B
-7.3x
---
As of 2024-07-21

Company Information

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Contact Information

Headquarters
3928 Point Eden WayHAYWARD, CA, United States 94545-3719
Phone
510-694-6200
Fax
302-730-1370

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Terry Rosen
President, Co-Founder
Juan Jaen
Chief Financial Officer
Robert Goeltz
Chief Operating Officer
Jennifer Jarrett
General Counsel
Carolyn Tang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.4B
Revenue (TTM)
$237.0M
Shares Outstanding
91.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.89
EPS
$-3.10
Book Value
$6.12
P/E Ratio
-4.6x
Price/Sales (TTM)
5.9
Price/Cash Flow (TTM)
---
Operating Margin
-113.92%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.